Fesoterodine
- Generic Name
- Fesoterodine
- Brand Names
- Toviaz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37NO3
- CAS Number
- 286930-02-7
- Unique Ingredient Identifier
- 621G617227
- Background
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
- Indication
适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
Fesoterodine "add-on" Male Overactive Bladder Study
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2011-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 947
- Registration Number
- NCT00546637
- Locations
- 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Chiang Mai, Thailand
Fesoterodine Flexible Dose Study
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 896
- Registration Number
- NCT00536484
- Locations
- 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1712
- Registration Number
- NCT00444925
- Locations
- 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 516
- Registration Number
- NCT00425100
- Locations
- 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder Syndrome
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220376
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder Syndrome
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220402
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
Phase 2
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220389
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder Syndrome
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220363
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00138723
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath